Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-25
2008-03-25
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S330000, C544S331000, C544S180000, C544S181000, C544S238000, C514S241000, C514S242000, C514S252010
Reexamination Certificate
active
10702113
ABSTRACT:
The present invention provides a compound of formula I:or a pharmaceutically acceptable salt thereof. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.
REFERENCES:
patent: 6949544 (2005-09-01), Bethiel et al.
patent: 2004/0147507 (2004-07-01), Ledeboer et al.
patent: WO 95/09847 (1995-04-01), None
patent: WO 95/09851 (1995-04-01), None
patent: WO 95/09853 (1995-04-01), None
patent: WO 97/19065 (1997-05-01), None
patent: WO 99/65897 (1999-12-01), None
patent: WO 01/29009 (2001-04-01), None
patent: WO-02/20495 (2002-03-01), None
patent: WO 02/22601 (2002-03-01), None
patent: WO 02/46170 (2002-06-01), None
patent: WO 02/46171 (2002-06-01), None
patent: WO 02/079193 (2002-10-01), None
patent: WO 02/079197 (2002-10-01), None
patent: WO 03/030909 (2003-04-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Duhe et al. Cell Biochem. Biophys. 34(1): 17-59, 2001.
Rane et al., Oncogene 19(49): 5662-79, 2000.
, Kim et al., Curr. Opin Genet Dev. 10(5): 508-514, 2000.
Mass, R. D., Int. J. Radiation Oncology Bio. Phys.vol. 58(3): 932-940, 2004.
Fabbro et al. Pharmacology & therapeutics 93, 79-98, 2002.
Ivashkiv et al., Arthritis & Rheumatism 48(8)2092-2096, 2003.
Changelian et al., “Prevention of organ allograft rejection by a specific janus kinase 3 inhibitor,” Science, 302:875-878, (2003).
Malaviya et al., “Treatment of allergic asthma be targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3′,5′—dibromo-4′-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97),” The Journal of Pharmacology and Experimental Therapeutics, 295(3):912-926, (2000).
Trieu et al., “A specific inhibitor of janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis,” Biochemical and Biophysical Research Communications, 267:22-25, (2000).
Bethiel Randy S.
Moon Young-Choon
Balasubramanian Venkataraman
Brown Karen E.
Vertex Pharmaceuticals Incorporated
LandOfFree
Compositions useful as inhibitors of JAK and other protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions useful as inhibitors of JAK and other protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions useful as inhibitors of JAK and other protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3959609